Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. - Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; et al. (JAMA neurology, 2024)